Evidence map›Paper›PMID 39015009›Full record

ArticleCancer biology & medicine2024

Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020.

Eleonora Feletto, Qingwei Luo, Anna Kelly, Marianne Weber, David Goldsbury, Katherine Barron, Karen Canfell, Xue Qin Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eleonora FelettoThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.ORCID 0000-0001-6192-4694
Qingwei LuoThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.
Anna KellyThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.
Marianne WeberThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.
David GoldsburyThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.
Katherine BarronThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.
Karen CanfellThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.
Xue Qin YuThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney NSW 2006, Australia.

Funding

Medical Research Future Fund (MRFF) Preventive and Public Health Research Initiative: 2019 Target Health System and Community Organisation Research Grant Opportunity MRF1200535National Health and Research Council of Australia Leadership Investigator NHMRC; APP1194679
6 · The paper itself

Abstract

objectiveAustralia has relatively high multiple myeloma (MM) incidence and mortality rates. Advancements in MM treatment over recent decades have driven improvements in MM survival in high-income countries; however, reporting in Australia is limited. We investigated temporal trends in population-wide MM survival across 3 periods of treatment advancements in New South Wales (NSW), Australia.

methodsIndividuals with an MM diagnosis in the NSW Cancer Registry between 1985 and 2015 with vital follow-up to 2020, were categorized into 3 previously defined treatment eras according to their diagnosis date (1985-1995, chemotherapy only; 1996-2007, autologous stem cell transplantation; and 2008-2015, novel agents including proteasome inhibitors and immunomodulatory drugs). Both relative survival and cause-specific survival according to Fine and Gray's competing risks cumulative incidence function were calculated by treatment era and age at diagnosis.

resultsOverall, 11,591 individuals were included in the study, with a median age of 70 years at diagnosis. Five-year relative survival improved over the 36-year (1985-2020) study period (31.0% in 1985-1995; 41.9% in 1996-2007; and 56.1% in 2008-2015). For individuals diagnosed before 70 years of age, the 5-year relative survival nearly doubled, from 36.5% in 1985-1995 to 68.5% in 2008-2015. Improvements for those > 70 years of age were less pronounced between 1985-1995 and 1996-2007; however, significant improvements were observed for those diagnosed in 2008-2015. Similar overall and age-specific patterns were observed for cause-specific survival. After adjustment for gender and age at diagnosis, treatment era was strongly associated with both relative and cause-specific survival (

conclusionsSurvival of individuals with MM is improving in Australia with treatment advances. However, older age groups continue to experience poor survival outcomes with only modest improvements over time. Given the increasing prevalence of MM in Australia, the effects of MM treatment on quality of life, particularly in older age, warrant further attention.

Indexed as

Multiple MyelomaAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedNew South WalesProteasome InhibitorsRegistriesSurvival RateTransplantation, AutologousProteasome InhibitorsAustraliacancer epidemiologycompeting risk analysisMultiple myelomasurvival analysis

Identifiers

PMID39015009
PMCPMC11359491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.